ASX Announcement | 26 October 2026 AdAlta Limited (ASX:1AD) QUARTERLY ACTIVITIES REPORT – SEPTEMBER QUARTER 2026 (Q1 FY27) EW-001 on the threshold of its first US FDA advice and first Australian manufacturing runs, as validation of AdAlta’s “East to West” strategy builds Investment...
Quarterly Appendix 4C and Activities Report
Filed with ASX ·
6ix is reading this filing.
Earlier from AdAlta
- RDTI receipt, Advanced Overseas Finding
- EW-001 JDC milestone approvals
- China Representative Office opens
- US FDA grants EW-001 pre-IND meeting
- Oribiotech deal validates AdAlta manufacturing strategy
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta